Laura García‐Estévez

Enzalutamide for the Treatment of Androgen Receptor–Expressing Triple-Negative Breast Cancer

Tiffany A. Traina, Kathy D. Miller, Denise A. Yardley et al. · Journal of Clinical Oncology · 2018 · 474 citations · Full text

Androgen Receptor, Breast Oncology, Medicine +15

Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial

Sung‐Bae Kim, Rebecca Dent, Seock‐Ah Im et al. · The Lancet Oncology · 2017 · 463 citations · Full text

First-line Therapy, Breast Oncology, Medicine +7

Results from a phase 2 study of enzalutamide (ENZA), an androgen receptor (AR) inhibitor, in advanced AR+ triple-negative breast cancer (TNBC).

Tiffany A. Traina, Kathy D. Miller, Denise A. Yardley et al. · Journal of Clinical Oncology · 2015 · 149 citations

Androgen Receptor, Breast Oncology, Pathology +17

A randomized phase II trial of platinum salts in basal-like breast cancer patients in the neoadjuvant setting. Results from the GEICAM/2006-03, multicenter study

Emilio Alba, José Ignacio Chacón, Aňa Lluch et al. · Breast Cancer Research and Treatment · 2012 · 143 citations · Full text

Neoadjuvant Setting, Oncology, Breast Oncology +10

A Phase II Randomized Study of Neoadjuvant Letrozole Plus Alpelisib for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer (NEO-ORB)

Ingrid A. Mayer, Aleix Prat, Daniel Egle et al. · Clinical Cancer Research · 2019 · 96 citations · Full text